This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

OncoMed Pharmaceuticals Presents Updated Phase 1a Data In Advanced Solid Tumor Patients For The First-in-Class WNT-Pathway-Targeting Antibody Vantictumab (OMP-18R5) At The European Cancer Congress 2013

Stocks in this article: OMED

Vantictumab is well tolerated and has surpassed the target efficacious dose from preclinical models

Vantictumab has pharmacodynamic effect on the WNT-pathway and evidence of single-agent activity

Vantictumab is advancing to combination Phase 1b studies in selected tumor types

REDWOOD CITY, Calif., Sept. 29, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today reported new data for vantictumab, a monoclonal antibody targeting the WNT pathway, at a poster session at the Joint ECCO 17, 38th ESMO and 32nd ESTRO European Cancer Congress 2013 (ECC 2013) in Amsterdam, The Netherlands.

In the ongoing Phase 1a clinical trial, 29 patients with advanced and refractory solid tumors were treated with single-agent vantictumab. To date the drug candidate has been well tolerated up to the current dose of 15 mg/kg every three weeks. This dose of vantictumab is above the target efficacious dose based on minimally passaged human tumor xenograft models. Vantictumab shows pharmacodynamic (PD) effects on the WNT-pathway in patient samples in the Phase 1 clinical trial. Evidence of single-agent activity of vantictumab is noted in several patients with neuroendocrine tumors (NETs). Based on these clinical results and data from preclinical patient-derived tumor models, OncoMed is initiating Phase 1b clinical trials in three tumor indications to study its safety in combination with standard-of-care chemotherapy. Vantictumab is part of OncoMed's Wnt pathway collaboration with Bayer Pharma AG.

Jakob Dupont, M.D., OncoMed's Chief Medical Officer commented, "We are encouraged that vantictumab can be administered safely in this study to patients at doses above the target efficacious doses extrapolated from our preclinical models. These results enable the advancement of vantictumab to three Phase 1b trials later this year."

"With ongoing clinical trials with five novel drug candidates in two key pathways, Notch and WNT, OncoMed is leading the way in the development of anti-cancer stem cell therapies," said Paul J. Hastings, Chairman and Chief Executive Officer of OncoMed.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs